Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Dr Reddy's Laboratories Ltd banner

Dr Reddy's Laboratories Ltd
NYSE:RDY

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
NYSE:RDY
Watchlist
Price: 12.14 USD 0.33% Market Closed
Market Cap: $2B
Write Note Create Alert Ask AI

Wall St Price Targets

RDY Price Targets Summary
Dr Reddy's Laboratories Ltd

Wall Street analysts forecast RDY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RDY is 12.93 USD with a low forecast of 10.54 USD and a high forecast of 18.35 USD.

RDY Lowest Forecast
Wall Street Target
$10.54
-13% Downside
RDY Average Forecast
Wall Street Target
$12.93
7% Upside
RDY Highest Forecast
Wall Street Target
$18.35
51% Upside
Lowest Forecast
Price Target
10.54 USD
13% Downside
Average Forecast
Price Target
12.93 USD
7% Upside
Highest Forecast
Price Target
18.35 USD
51% Upside
Dr Reddy's Laboratories Ltd Competitors:
Price Targets
FCBC
First Community Bankshares Inc
-6% Downside
FCBC
First Community Bankshares Inc
-6% Downside

Revenue
Forecast

8% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
8% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 4 years is 8%.

What are analyst estimates?

Gross Profit
Forecast

8% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
15%
Average Beat
8% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
15%
Average Beat

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 4 years is 6%.

What are analyst estimates?

Operating Income
Forecast

6% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
6% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 4 years is 18%.

What are analyst estimates?

Pre-Tax Income
Forecast

7% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
7% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 2 years is 17%.

What are analyst estimates?

Net Income
Forecast

8% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
8% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 4 years is 16%.

What are analyst estimates?

Continue RDY Research

Summary
RDY intrinsic value, competitors valuation, and company profile.
DCF Valuation
RDY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RDY stock valuation using valuation multiples.
Wall St Estimates
RDY price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RDY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Dr Reddy's Laboratories Ltd listings:
F • EUR
RDDA
 BSE • INR
500124
 NSE • INR
DRREDDY
 SWB • EUR
RDDA
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RDY's stock price target?
Price Target
12.93 USD

According to Wall Street analysts, the average 1-year price target for RDY is 12.93 USD with a low forecast of 10.54 USD and a high forecast of 18.35 USD.

What is the Revenue forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 4 years is 8%.

What is the Gross Profit forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 4 years is 6%.

What is the Operating Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 4 years is 18%.

What is the Pre-Tax Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
17%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 2 years is 17%.

What is the Net Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 4 years is 16%.

Back to Top
ALPHA SPREAD
Follow us
Join 351,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett